Evidence map›Paper›PMID 39698547›Full record

ArticleACS ES&T water2024

A Robust High-Pressure RO Technology to Overcome the Barriers to Full Circularity in Cr(III) Electroplating Operations.

Roxanne Engstler, Ebrahim Hosseinipour, Seval Yilmaz, Felix Heinzler, Marvin Wagner, Mathias Ulbricht, Philip Davies, Stéphan Barbe

Abstract read
In one paragraph

Article in ACS ES&T water, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Roxanne EngstlerFaculty of Applied Natural Sciences, Technische Hochschule Köln, 51379 Leverkusen, Germany.ORCID https://orcid.org/0000-0002-5556-0393
Ebrahim HosseinipourSchool of Engineering, University of Birmingham, B15 2FG Birmingham, U.K.
Seval YilmazSchool of Engineering, University of Birmingham, B15 2FG Birmingham, U.K.
Felix HeinzlerBIA Kunststoff- und Galvanotechnik GmbH & Co. KG, 42655 Solingen, Germany.
Marvin WagnerBIA Kunststoff- und Galvanotechnik GmbH & Co. KG, 42655 Solingen, Germany.
Mathias UlbrichtDepartment of Technical Chemistry II, University of Duisburg-Essen, 45141 Essen, Germany.ORCID https://orcid.org/0000-0002-2094-0708
Philip DaviesSchool of Engineering, University of Birmingham, B15 2FG Birmingham, U.K.
Stéphan BarbeFaculty of Applied Natural Sciences, Technische Hochschule Köln, 51379 Leverkusen, Germany.ORCID https://orcid.org/0000-0002-2256-980X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Electroplating is a widely used technology for anticorrosion materials and decorative coatings. In view of the transition to a circular economy, the current electroplating wastewater treatment disposing of heavy metal sludge and wastewater severely lacks sustainability. Authors recently reported the successful recycling of electroplating agents using hybrid semibatch/batch reverse osmosis technology (hybrid RO). Despite promising results, technology assessment to treat new, second-generation electrolytes, enhance boric acid recovery, close the water loops, and evaluate process robustness is still needed. This study investigates the viability of a high-pressure (120 bar) hybrid RO system, working with the DuPont XUS180808 membrane, to reclaim valuable second-generation plating components and water from electroplating rinses. The pilot-scale system showcased resilience in processing artificial electroplating wastewaters of variable concentration, achieving water recoveries of ≤87.7%, increasing chromium and sulfate to electrolyte levels (>6 g/L and >80 g/L), with low energy consumptions (≤2.7 kWh/m

Identifiers

PMID39698547
PMCPMC11650646

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.